A phase I, dose escalation, safety, and immunogenicity trial of an alphavirus replicon HIV-1 subtype C Gag vaccine (AVX101) in healthy HIV-1 uninfected adult participants

Trial Profile

A phase I, dose escalation, safety, and immunogenicity trial of an alphavirus replicon HIV-1 subtype C Gag vaccine (AVX101) in healthy HIV-1 uninfected adult participants

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2012

At a glance

  • Drugs AVX 101 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jun 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 29 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top